Medications for Melanoma
13 results
Braftovi (encorafenib)
(Encorafenib)Array BioPharma Inc.
Usage: BRAFTOVI is indicated for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer (mCRC), and metastatic non-small cell lung cancer (NSCLC) with BRAF V600E or V600K mutations when used with specific combinations. It is not meant for wild-type BRAF tumors.
Cotellic (cobimetinib)
(COBIMETINIB)Genentech, Inc.
Usage: COTELLIC® is indicated for treating adult patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, in combination with vemurafenib, and as a single agent for adult patients with histiocytic neoplasms.
Imlygic (talimogene laherparepvec)
(talimogene laherparepvec)Amgen Inc
Usage: IMLYGIC is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions that recur after initial surgery. It does not improve overall survival or address visceral metastases.
Keytruda (pembrolizumab)
(pembrolizumab)Merck Sharp & Dohme LLC
Usage: KEYTRUDA® is indicated for treating various cancers, including melanoma, non-small cell lung cancer, malignant pleural mesothelioma, head and neck squamous cell cancer, classical Hodgkin lymphoma, and possible others, in both adults and children, depending on specific tumor characteristics and treatment history.
Cardinal Health 414, LLC
Usage: Lymphoseek is indicated for lymphatic mapping and guiding sentinel lymph node biopsy in adult and pediatric patients (ages one month and older) with solid tumors, including squamous cell carcinoma, breast cancer, or melanoma, utilizing a handheld gamma counter.
Mektovi (binimetinib)
(BINIMETINIB)Array BioPharma Inc.
Usage: MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E or V600K mutations, as confirmed by FDA-approved tests.
Opdivo (nivolumab)
(nivolumab)E.R. Squibb & Sons, L.L.C.
Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, advanced renal cell carcinoma (RCC), classical Hodgkin lymphoma, and more, in both adults and pediatric patients. It can be used alone or in combination therapies.
Opdualag (nivolumab and relatlimab-rmbw)
(nivolumab and relatlimab-rmbw)E.R. Squibb & Sons, L.L.C.
Usage: OPDUALAG™ is indicated for treating adult and pediatric patients aged 12 and older with unresectable or metastatic melanoma.
Proleukin (aldesleukin)
(aldesleukin)Clinigen Limited
Usage: Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma.
Proleukin (aldesleukin)
(aldesleukin)Prometheus Laboratories Inc.
Usage: Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma. Patient selection is crucial, emphasizing the need for screening and assessment of performance status to optimize response rates and minimize toxicity.